Systematic ReviewSystematic Review
Open Access

The potential role of nutritional components in improving brain function among patients with Alzheimer’s disease: a meta-analysis of RCT studies

Tarfa Albrahim
Neurosciences Journal January 2020, 25 (1) 4-17; DOI: https://doi.org/10.17712/nsj.2020.1.20190037

References

  1. ↵
    1. Lunenfeld B,
    2. Stratton P
    (2013) The clinical consequences of an ageing world and preventive strategies. Best Pract Res Clin Obstet Gynaecol 27, 643–659.
    OpenUrlCrossRefPubMed
    1. Solfrizzi V,
    2. Panza F,
    3. Frisardi V,
    4. Seripa D,
    5. Logroscino G,
    6. Imbimbo BP,
    7. et al.
    (2011) Diet and Alzheimer’s disease risk factors or prevention: the current evidence. Expert review of neurotherapeutics 11, 677–708.
    OpenUrl
  3. ↵
    1. Lane CA,
    2. Hardy J,
    3. Schott JM
    (2018) Alzheimer’s disease. European journal of neurology 25, 59–70.
    OpenUrlCrossRefPubMed
  4. ↵
    1. von Arnim CA,
    2. Gola U,
    3. Biesalski HK
    (2010) More than the sum of its parts? Nutrition in Alzheimer’s disease. Nutrition 26, 694–700.
    OpenUrlCrossRefPubMed
  5. ↵
    1. World Health Organization
    Alzheimer Disease and other Dementias, [Cited 2004] from: https://www.who.int/medicines/areas/priority_medicines/Ch6_11Alzheimer.pdf.
  6. ↵
    1. Morris MC
    (2009) The role of nutrition in Alzheimer’s disease: epidemiological evidence. European journal of neurology 16, 1–7.
    OpenUrlPubMed
    1. Ikeda T,
    2. Yamada M
    (2010) [Risk factors for Alzheimer’s disease]. Brain Nerve 62, 679–690, Japanese.
    OpenUrlPubMed
  8. ↵
    1. Tolppanen AM,
    2. Taipale H,
    3. Hartikainen S
    (2017) Head or brain injuries and Alzheimer’s disease: A nested case-control register study. Alzheimers Dement 13, 1371–1379.
    OpenUrl
  9. ↵
    1. Seneff S,
    2. Wainwright G,
    3. Mascitelli L
    (2011) Nutrition and Alzheimer’s disease: the detrimental role of a high carbohydrate diet. Eur J Intern Med 22, 134–140.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Feng Y,
    2. Wang X
    (2012) Antioxidant therapies for Alzheimer’s disease. Oxid Med Cell Longev 2012, 472932.
    OpenUrlPubMed
  11. ↵
    1. Aliev G,
    2. Obrenovich ME,
    3. Reddy VP,
    4. Shenk JC,
    5. Moreira PI,
    6. Nunomura A,
    7. et al.
    (2008) Antioxidant therapy in Alzheimer’s disease: theory and practice. Mini Rev Med Chem 8, 1395–1406.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Fenech M
    (2017) Vitamins Associated with Brain Aging, Mild Cognitive Impairment, and Alzheimer Disease: Biomarkers, Epidemiological and Experimental Evidence, Plausible Mechanisms, and Knowledge Gaps. Adv Nutr 8, 958–970.
    OpenUrlAbstract/FREE Full Text
    1. Boccardi V,
    2. Baroni M,
    3. Mangialasche F,
    4. Mecocci P
    (2016) Vitamin E family: Role in the pathogenesis and treatment of Alzheimer’s disease. Alzheimers Dement(NY) 2, 182–191.
    OpenUrl
  14. ↵
    1. Licher S,
    2. de Bruijn R,
    3. Wolters FJ,
    4. Zillikens MC,
    5. Ikram MA,
    6. Ikram MK
    (2017) Vitamin D and the Risk of Dementia: The Rotterdam Study. J Alzheimers Dis 60, 989–997.
    OpenUrl
  15. ↵
    1. Sawda C,
    2. Moussa C,
    3. Turner RS
    (2017) Resveratrol for Alzheimer’s disease. Ann N Y Acad Sci 1403, 142–149.
    OpenUrl
  16. ↵
    1. Tang M,
    2. Taghibiglou C
    (2017) The Mechanisms of Action of Curcumin in Alzheimer’s Disease. J Alzheimers Dis 58, 1003–1016.
    OpenUrlCrossRef
  17. ↵
    1. Huang TL
    (2010) Omega-3 fatty acids, cognitive decline, and Alzheimer’s disease: a critical review and evaluation of the literature. J Alzheimers Dis 21, 673–690.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Canhada S,
    2. Castro K,
    3. Perry IS,
    4. Luft VC
    (2018) Omega-3 fatty acids’ supplementation in Alzheimer’s disease: A systematic review. Nutr Neurosci 21, 529–38.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Barnard ND,
    2. Bunner AE,
    3. Agarwal U
    (2014) Saturated and trans fats and dementia: a systematic review. Neurobiol Aging 35, S65–S73.
    OpenUrl
  20. ↵
    1. Henderson ST
    (2004) High carbohydrate diets and Alzheimer’s disease. Medical hypotheses 62, 689–700.
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    1. Rochoy M,
    2. Rivas V,
    3. Chazard E,
    4. Decarpentry E,
    5. Saudemont G,
    6. Hazard PA,
    7. et al.
    (2019) Factors Associated with Alzheimer’s Disease: An Overview of Reviews. J Prev Alzheimers Dis 6, 121–134.
    OpenUrlCrossRef
  22. ↵
    1. Sofi F,
    2. Cesari F,
    3. Abbate R,
    4. Gensini GF,
    5. Casini A
    (2008) Adherence to Mediterranean diet and health status: meta-analysis. BMJ 337, a1344.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Dysken MW,
    2. Sano M,
    3. Asthana S,
    4. Vertrees JE,
    5. Pallaki M,
    6. Llorente M,
    7. et al.
    (2014) Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA 311, 33–44.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    1. Arlt S,
    2. Muller-Thomsen T,
    3. Beisiegel U,
    4. Kontush A
    (2012) Effect of one-year vitamin C- and E-supplementation on cerebrospinal fluid oxidation parameters and clinical course in Alzheimer’s disease. Neurochem Res 37, 2706–2714.
    OpenUrlPubMed
  25. ↵
    1. Ringman JM,
    2. Frautschy SA,
    3. Teng E,
    4. Begum AN,
    5. Bardens J,
    6. Beigi M,
    7. et al.
    (2012) Oral curcumin for Alzheimer’s disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimers Res Ther 4, 43.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Galasko DR,
    2. Peskind E,
    3. Clark CM,
    4. Quinn JF,
    5. Ringman JM,
    6. Jicha GA,
    7. et al.
    (2012) Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol 69, 836–841.
    OpenUrlCrossRefPubMed
  27. ↵
    1. de Waal H,
    2. Stam CJ,
    3. Lansbergen MM,
    4. Wieggers RL,
    5. Kamphuis PJ,
    6. Scheltens P,
    7. et al.
    (2014) The effect of souvenaid on functional brain network organisation in patients with mild Alzheimer’s disease: a randomised controlled study. PLoS One 9, e86558.
    OpenUrl
  28. ↵
    1. Shinto L,
    2. Quinn J,
    3. Montine T,
    4. Dodge HH,
    5. Woodward W,
    6. Baldauf-Wagner S,
    7. et al.
    (2014) A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer’s disease. J Alzheimers Dis 38, 111–120.
    OpenUrlCrossRefPubMedWeb of Science
  29. ↵
    1. Faxén-Irving G,
    2. Freund-Levi Y,
    3. Eriksdotter-Jönhagen M,
    4. Basun H,
    5. Hjorth E,
    6. Palmblad J,
    7. et al.
    (2013) Effects on transthyretin in plasma and cerebrospinal fluid by DHA-rich n - 3 fatty acid supplementation in patients with Alzheimer’s disease: the OmegAD study. J Alzheimers Dis 36, 1–6.
    OpenUrlPubMed
  30. ↵
    1. Quinn JF,
    2. Raman R,
    3. Thomas RG,
    4. Yurko-Mauro K,
    5. Nelson EB,
    6. Van Dyck C,
    7. et al.
    (2010) Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA 304, 1903–1911.
    OpenUrlCrossRefPubMedWeb of Science
  31. ↵
    1. Kamphuis PJ,
    2. Verhey FR,
    3. Olde Rikkert MG,
    4. Twisk JW,
    5. Swinkels SH,
    6. Scheltens P
    (2011) Effect of a medical food on body mass index and activities of daily living in patients with Alzheimer’s disease: secondary analyses from a randomized, controlled trial. J Nutr Health Aging 15, 672–676.
    OpenUrlPubMed
    1. Remington R,
    2. Bechtel C,
    3. Larsen D,
    4. Samar A,
    5. Doshanjh L,
    6. Fishman P,
    7. et al.
    (2015) A Phase II Randomized Clinical Trial of a Nutritional Formulation for Cognition and Mood in Alzheimer’s Disease. J Alzheimers Dis 45, 395–405.
    OpenUrlPubMed
  33. ↵
    1. Shah RC,
    2. Kamphuis PJ,
    3. Leurgans S,
    4. Swinkels SH,
    5. Sadowsky CH,
    6. Bongers A,
    7. et al.
    (2013) The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer’s disease. Alzheimers Res Ther 5, 59.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Astarita G,
    2. Jung KM,
    3. Berchtold NC,
    4. Nguyen VQ,
    5. Gillen DL,
    6. Head E,
    7. et al.
    (2010) Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer’s disease. PloS one 5, e12538.
    OpenUrlCrossRefPubMed
  35. ↵
    1. Fonteh AN,
    2. Cipolla M,
    3. Chiang J,
    4. Arakaki X,
    5. Harrington MG
    (2014) Human cerebrospinal fluid fatty acid levels differ between supernatant fluid and brain-derived nanoparticle fractions, and are altered in Alzheimer’s disease. PLoS One 9, e100519.
    OpenUrlCrossRefPubMed
    1. Fraser T,
    2. Tayler H,
    3. Love S
    (2010) Fatty acid composition of frontal, temporal and parietal neocortex in the normal human brain and in Alzheimer’s disease. Neurochem Res 35, 503–513.
    OpenUrlPubMed
  37. ↵
    1. Igarashi M,
    2. Ma K,
    3. Gao F,
    4. Kim HW,
    5. Rapoport SI,
    6. Rao JS
    (2011) Disturbed choline plasmalogen and phospholipid fatty acid concentrations in Alzheimer’s disease prefrontal cortex. J Alzheimers Dis 24, 507–517.
    OpenUrlPubMed
    1. Martin V,
    2. Fabelo N,
    3. Santpere G,
    4. Puig B,
    5. Marin R,
    6. Ferrer I,
    7. et al.
    (2010) Lipid alterations in lipid rafts from Alzheimer’s disease human brain cortex. J Alzheimers Dis 19, 489–502.
    OpenUrlCrossRefPubMed
  39. ↵
    1. Scheltens P,
    2. Kamphuis PJ,
    3. Verhey FR,
    4. Olde Rikkert MG,
    5. Wurtman RJ,
    6. Wilkinson D,
    7. et al.
    (2010) Efficacy of a medical food in mild Alzheimer’s disease: A randomized, controlled trial. Alzheimers Dement 6, 1–10.e1.
    OpenUrlCrossRefPubMedWeb of Science
  40. ↵
    1. Kaddurah-Daouk R,
    2. Rozen S,
    3. Matson W,
    4. Han X,
    5. Hulette CM,
    6. Burke JR,
    7. et al.
    (2011) Metabolomic changes in autopsy-confirmed Alzheimer’s disease. Alzheimers Dement 7, 309–317.
    OpenUrlCrossRefPubMed
  41. ↵
    1. Scheltens P,
    2. Twisk JW,
    3. Blesa R,
    4. Scarpini E,
    5. von Arnim CA,
    6. Bongers A,
    7. et al.
    (2012) Efficacy of Souvenaid in mild Alzheimer’s disease: results from a randomized, controlled trial. J Alzheimers Dis 31, 225–236.
    OpenUrlCrossRefPubMedWeb of Science
  42. ↵
    1. Douaud G,
    2. Refsum H,
    3. de Jager CA,
    4. Jacoby R,
    5. Nichols TE,
    6. Smith SM,
    7. et al.
    (2013) Preventing Alzheimer’s disease-related gray matter atrophy by B-vitamin treatment. Proc Natl Acad Sci U S A 110, 9523–9528.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    1. de Jager CA,
    2. Oulhaj A,
    3. Jacoby R,
    4. Refsum H,
    5. Smith AD
    (2012) Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. Int J Geriatr Psychiatry 27, 592–600.
    OpenUrlCrossRefPubMed
  44. ↵
    1. Kwok T,
    2. Lee J,
    3. Law CB,
    4. Pan PC,
    5. Yung CY,
    6. Choi KC,
    7. et al.
    (2011) A randomized placebo controlled trial of homocysteine lowering to reduce cognitive decline in older demented people. Clinical nutrition 30, 297–302.
    OpenUrlCrossRefPubMed
  45. ↵
    1. Smith AD,
    2. Smith SM,
    3. de Jager CA,
    4. Whitbread P,
    5. Johnston C,
    6. Agacinski G,
    7. et al.
    (2010) Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PloS one 5, e12244.
    OpenUrlCrossRefPubMed
  46. ↵
    1. Hu N,
    2. Yu JT,
    3. Tan L,
    4. Wang YL,
    5. Sun L,
    6. Tan L
    (2013) Nutrition and the risk of Alzheimer’s disease. Biomed Res Int 2013, 524820.
    OpenUrl
  47. ↵
    1. Gibson TM,
    2. Ferrucci LM,
    3. Tangrea JA,
    4. Schatzkin A
    (2010) Epidemiological and clinical studies of nutrition. Semin Oncol 37, 282–296.
    OpenUrlCrossRefPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section